Invivoscribe Marketing, Author at Invivoscribe - Page 4 of 6

PRODUCTS
- Reagents
  ASRs
  Enzymes
  Hi-Di Formamide
- 2024 Product & Service Catalogs
CLINICAL LAB SERVICES
- Clinical Lab Services Overview
  The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.
  EXPLORE SERVICES ⟶
- Flow Cytometry
  Hematolymphoid Screening Panel
  AML MRD Assay
  CLL MRD Assay
- Companion Diagnostic (CDx) Tests
  CDx – USA
  CDx – Germany
  CDx – Japan
- NGS Cancer Panels
  MyAML
  MyMRD
- MRD NGS Tests
  Clonality
  FLT3 ITD
  NPM1
- Clonality NGS Tests
  SHM
  IGH
  IGK
  TRG
  TRB
BIOBANK REPOSITORY
DISEASES
- Lymphoid
  Mature B-cell
  Mature T-cell
  
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  
  LEARN MORE ⟶
- Myeloid
  Myelodysplastic Syndromes (MDS)
  Acute Myeloid Leukemia (AML)
  Myeloproliferative Neoplasms (MPNs)
  
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  
  LEARN MORE ⟶
- Hematological Testing Menu
  Browse our comprehensive menu of product & testing services.
  EXPLORE MENU ⟶
PARTNERSHIPS
- Partnerships Overview
  A proven strategy to accelerate drug approvals
  EXPLORE PARTNERSHIPS ⟶
  CE-IVD
  LeukoStrat products are used worldwide to determine the mutation status of the FLT3 and NPM1 biomarkers.
  LEARN MORE ⟶
- Product Development
  Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays
  EXPLORE ⟶
  CE-IVD
  IdentiClone assays are intended for PCR-based detection of clonal gene rearrangements and translocations.
  LEARN MORE ⟶
- Manufacturing
  cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents
  EXPLORE ⟶
- LabPMM®
  Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment
  EXPLORE ⟶
- Global Regulatory Expertise
  Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)
  EXPLORE ⟶
SCIENCE
- Science Overview
  We take pride in expanding the science that bridges personalized medicine with quality healthcare.
  EXPLORE OUR SCIENCE ⟶
- Personalized Medicine
  Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.
  EXPLORE PERSONALIZED MEDICINE ⟶
PUBLICATIONS
- Featured Publication
  Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
  VIEW PUBLICATION ⟶
- Latest Publications
  Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
  VIEW PUBLICATION ⟶
  Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing
  VIEW PUBLICATION ⟶
  Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma
  VIEW PUBLICATION ⟶
COMPANY
- Company
  About Us
  Our Mission, Vision & Values
  Leadership Team
  Board of Directors
  Legal Notices
  Newsroom
  Global Distributors
  Licensure and Certifications
  Careers & Culture
  Shop Corporate Gear
- Invivoscribe Locations
  
  Invivoscribe, Inc. (USA)
  San Diego, CA, US
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  Marseille, France
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  Shanghai, China
  CONTACT US ⟶
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  LEARN MORE ⟶
- Clinical Lab Locations
  
  LabPMM, LLC (USA)
  San Diego, CA, US
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  Munich, Germany
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  Kawasaki, Japan
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  Shanghai, China
  CONTACT US ⟶
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  LEARN MORE ⟶
- Support
  
  Invivoscribe, Inc. (USA)
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  CONTACT US ⟶
  
  LabPMM, LLC (USA)
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  CONTACT US ⟶
  Search for:
Search
- Search Articles & Publications
  Search for:
- Search Products & Services
  SEARCH ⟶
- Search Product Documents & IFUs
  SEARCH ⟶

About Invivoscribe Marketing

This author has not yet filled in any details.
So far Invivoscribe Marketing has created 146 blog entries.

Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides

Invivoscribe Marketing2021-02-11T21:43:52-08:00June 8th, 2020|2020 Publications, Publications|

Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing

Invivoscribe Marketing2021-02-11T21:47:46-08:00May 19th, 2020|2020 Publications, Publications|

Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States

Invivoscribe Marketing2021-02-26T19:09:52-08:00May 19th, 2020|2020 Press Releases, Press Releases|

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe Marketing2020-05-27T18:13:43-07:00May 15th, 2020|Events, Upcoming Events|

Invivoscribe to Exhibit at 25th EHA Annual Congress

Invivoscribe Marketing2020-05-27T18:11:58-07:00May 15th, 2020|Events, Upcoming Events|

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

Invivoscribe Marketing2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases|

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Invivoscribe Marketing2021-02-15T19:48:14-08:00May 6th, 2020|2020 Publications, Publications|

Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Invivoscribe Marketing2021-02-11T21:50:38-08:00May 1st, 2020|2020 Publications, Publications|

Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status

Invivoscribe Marketing2021-02-11T21:53:32-08:00April 1st, 2020|2020 Publications, Publications|

Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications

Invivoscribe Marketing2021-02-11T21:56:18-08:00March 1st, 2020|2020 Publications, Publications|

Clinical Utility of NGS in Lymphoid Malignancies

Invivoscribe Marketing2022-05-25T03:00:59-07:00February 27th, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Invivoscribe Marketing2021-02-11T21:58:45-08:00February 6th, 2020|2020 Publications, Publications|

Monitoring minimal residual disease in the bone marrow using next generation sequencing

Invivoscribe Marketing2021-02-11T22:00:56-08:00January 17th, 2020|2020 Publications, Publications|

The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

Invivoscribe Marketing2021-11-14T22:08:08-08:00December 5th, 2019|2019 Press Releases, Press Releases|

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence

Invivoscribe Marketing2021-02-11T23:36:10-08:00November 13th, 2019|2019 Publications, Publications|

AMP 2019 Video Series Part 4 of 4

Invivoscribe Marketing2022-05-25T03:00:59-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

AMP 2019 Video Series Part 3 of 4

Invivoscribe Marketing2022-05-25T03:00:59-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

AMP 2019 Video Series Part 2 of 4

Invivoscribe Marketing2022-05-25T03:00:59-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

AMP 2019 Video Series Part 1 of 4

Invivoscribe Marketing2022-05-25T03:01:00-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

Invivoscribe Marketing2021-02-11T23:40:44-08:00October 15th, 2019|2019 Publications, Publications|

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

Invivoscribe Marketing2021-02-11T23:43:09-08:00October 1st, 2019|2019 Publications, Publications|

NOW AVAILABLE! MRD solutions for B- and T-cell clonality tracking

Invivoscribe Marketing2019-09-23T22:05:58-07:00August 26th, 2019|Product Releases|

Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA

Invivoscribe Marketing2021-02-26T19:10:37-08:00June 19th, 2019|2019 Press Releases, Press Releases|

Invivoscribe – EHA 2019: Part 3 of 3

Invivoscribe Marketing2022-05-25T03:01:00-07:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Invivoscribe – EHA 2019: Part 2 of 3

Invivoscribe Marketing2022-05-25T03:01:00-07:00June 13th, 2019|2019 Videos, Featured Videos, Videos|